Markets
Sareum Phase 1 Autoimmune Data: What the Clinical Readout Means for SAR442168 and the Stock
Sareum Holdings has released Phase 1 clinical trial data for its lead autoimmune drug candidate, a milestone that shifts the company from pure speculation to early evidence-backed biotech. Here's what the data means for the stock and the sector.